FABP Biotech is a spin-off of the Oswaldo Cruz Foundation created to develop anti-helminth vaccines for animal use. The company holds the exclusive rights for the development and commercialization of vaccines and veterinary products based on Sm14.

FABP’s business model is grounded on strategic alliances to bring the Sm14-derived products in our pipeline to regulatory approval globally. Through partnerships with local companies well-versed in regional regulatory systems, we can bring cutting edge and innovative biotechnological solutions to the market, promoting animal health.